周三盘中，云顶新耀-B（01952.HK）股价大涨5.23%，引起市场关注。这一显著涨幅主要受到中金公司最新研究报告的推动。
中金报告指出，云顶新耀战略聚焦肾病领域和mRNA肿瘤疫苗，并取得积极进展。在肾病治疗领域，除已上市的耐赋康外，公司正在开发新一代共价可逆BTK抑制剂EVER001，其前期临床试验结果积极。在mRNA肿瘤疫苗领域，公司的个性化肿瘤疫苗EVM16已在国内启动临床试验，而通用型现货肿瘤治疗性疫苗EVM14也获得美国FDA新药临床试验批准。
基于公司EVER001及mRNA肿瘤疫苗的研发进展开始在估值中体现，中金大幅上调云顶新耀的目标价133%至70元，维持"跑赢行业"评级。此外，公司近期宣布授出大量购股权，这可能进一步提振了投资者信心。分析人士认为，这些因素共同推动了云顶新耀股价的强劲表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.